TSET Health Promotion Research Center, Stephenson Cancer Center, University of Oklahoma Health Sciences Center, Oklahoma, OK, USA.
Department of Pediatrics, College of Medicine, University of Oklahoma Health Sciences Center, Oklahoma, OK, USA.
Sci Rep. 2024 Nov 16;14(1):28319. doi: 10.1038/s41598-024-78501-4.
Adults with cancer may perceive cannabis as beneficial for managing their cancer-related symptoms, but the evidence supporting its medical use is varied and inconclusive. This study characterized associations of cannabis use with cancer-related symptom trajectories. Participants were adults undergoing cancer treatment at the Stephenson Cancer Center (SCC; n = 218) in Oklahoma; they were 71% female, 10% minoritized race, and 45% had stage III or IV cancer. Participants completed surveys at baseline and 2-, 4-, and 6-months post-baseline. Assessments queried about cannabis use behavior, physical and psychological distress via the Rotterdam Symptoms Checklist (RSCL), respiratory symptoms via the American Thoracic Society Questionnaire (ATSQ), and quality of life indices (physical and social functioning, pain interference, sleep quality, fatigue) via the Patient Reported Outcomes Measurement Information System (PROMIS-29). Cannabis use status was categorized based on self-reported past 30-day cannabis use at each assessment as non-use [no use at any assessment], occasional-use [use at 1-2 assessments], or consistent-use [use at 3-4 assessments]. Longitudinal hierarchical linear modeling evaluated associations of cannabis use status with average symptoms and symptom trajectories across all four assessments. One-third (33%) of participants reported past 30-day cannabis use at ≥ 1 assessment. Participants who reported cannabis use (occasional-use and consistent-use) had more severe symptoms overall across assessments. While most cancer symptom trajectories did not differ by cannabis use status, participants who reported consistent cannabis use uniquely showed worsening physical function over time. Cannabis use was associated with greater cancer-related symptom severity over time.
成年人可能认为大麻有益于缓解癌症相关症状,但支持其医学用途的证据存在差异且不明确。本研究旨在描述大麻使用与癌症相关症状轨迹之间的关联。参与者为在俄克拉荷马州斯蒂芬森癌症中心(SCC)接受癌症治疗的成年人(n=218);其中 71%为女性,10%为少数族裔,45%为 III 期或 IV 期癌症患者。参与者在基线和基线后 2、4 和 6 个月完成调查。评估内容包括大麻使用行为、通过罗特堡症状清单(RSCL)评估的身体和心理困扰、通过美国胸科学会问卷(ATSQ)评估的呼吸症状,以及通过患者报告的结果测量信息系统(PROMIS-29)评估的生活质量指数(身体和社会功能、疼痛干扰、睡眠质量、疲劳)。大麻使用状况基于每个评估时的自我报告的过去 30 天大麻使用情况进行分类,分为非使用(任何评估时均未使用)、偶尔使用(1-2 次评估时使用)或持续使用(3-4 次评估时使用)。纵向分层线性建模评估了大麻使用状况与所有四次评估的平均症状和症状轨迹之间的关联。三分之一(33%)的参与者在至少一次评估中报告了过去 30 天的大麻使用情况。报告使用大麻(偶尔使用和持续使用)的参与者在所有评估中整体症状更严重。虽然大多数癌症症状轨迹不受大麻使用状况的影响,但报告持续使用大麻的参与者在身体功能方面表现出随时间恶化的独特趋势。大麻使用与癌症相关症状的严重程度随时间推移而增加有关。